Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results - Blockonomi
Definium Therapeutics (DFTX) stock rose 20% after DT120 ODT met Phase 3 endpoints for GAD treatment. NDA submission planned for H1 2027.
14 Sep 14:23 · Blockonomi